https://www.selleckchem.com/
70 (95% CI 1.67-1.73); I 2 = 0%; P less then 0.00001], and changes in body weight [MD -1.43 (95% CI -2.15 to -0.72); I 2 = 84%; P less then 0.0001) from baseline. However, empagliflozin did not show a better change in the 6-min walk test (6MWT) [MD 34.06 (95% CI -29.75-97.88); I 2 = 97%; P = 0.30] or NT-proBNP [MD -98.36 (95% CI, -225.83-29.11); I 2 = 68%; P = 0.13] from baseline. Conclusion The findings suggest that empagliflozin was effective in reducing a composite of cardiovascular death or hospitalization for worsening heart failure. Further well-desig
Like
Comment
Share
